IP Library Granted Patent US 8,288,515
Granted Patent B2
US 8,288,515 · App. 12/847,719 · Granted Oct 16, 2012

Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,288,515
App. No.
12/847,719
Granted
Oct 16, 2012
Kind
B2
Abstract

Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.

Claims (39)

1. A compound of Formula I

wherein

R 1 is levulinyl (Lev) or tetrahydropyran (THP);

R 2 is —O − or a salt thereof, —OH, —OAcyl, or —OSO 3 − or a salt thereof;

R 3 is H, benzyl or a protecting group removable by hydrogenation;

R 4 is N 3 (azide), NH 2 , NH-protecting group, or NHSO 3 − or a salt thereof;

R 5 is C 1 -C 6 alkyl; and

R 6 and R 7 are independently selected from —CO 2 − or a salt thereof, —CO 2 H and —CO 2 R x where R x is a C 1 -C 6 alkyl, aryl, C 1 -C 4 alkoxy(aryl), aryl(C 1 -C 6 alkyl), or C 1 -C 4 alkoxy(aryl)(C 1 -C 6 alkyl); and

wherein said compound has alpha (α) stereochemistry at the carbon bearing the —OR 5 group.

2. The compound of claim 1 wherein R 2 is —O-acetyl or —O-benzoyl.

3. The compound of claim 1 wherein R 2 is −O − , —ONa, —OLi, —OK or —OCs.

4. The compound of claim 1 , wherein R 2 is —OSO 3 − , —OSO 3 Na, —OSO 3 Li, —OSO 3 K or —OSO 3 Cs.

5. The compound of claim 1 , wherein R 5 is methyl.

6. The compound of claim 1 , wherein R 3 is benzyl or p-methoxybenzyl.

7. The compound of claim 1 , wherein R 3 is —CO 2 − , —CO 2 Na, —CO 2 Li, —CO 2 K or —CO 2 Cs.

8. The compound of claim 1 , wherein R 1 is levulinyl (Lev), R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me.

9. The compound of claim 1 , wherein R 1 is tetrahydropyran (THP), R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me.

10. The compound of claim 1 , wherein R 1 is tetrahydropyran (THP), R 2 is —O − or a salt thereof, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof.

11. The compound of claim 1 , wherein R 1 is tetrahydropyran (THP), R 2 is —OSO 3 − or a salt thereof, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof.

12. The compound of claim 1 , wherein R 1 is tetrahydropyran (THP), R 2 is —OSO 3 − or a salt thereof, R 3 is H, R 4 is NH 2 , R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof.

13. The compound of claim 1 , wherein R 1 is tetrahydropyran (THP), R 2 is —OSO 3 Na, R 3 is H, R 4 is NHSO 3 Na, R 5 is methyl, and R 6 and R 7 are —CO 2 Na.

14. A compound of Formula I

wherein R 1 is H, R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me.

15. A compound selected from:

16. A composition comprising (i) Fondaparinux sodium and (ii) a compound selected from:

and combinations thereof.

17. The composition of claim 16 , wherein the composition contains at least 95% by weight of Fondaparinux sodium and up to 0.2% of each of compounds P2, P3, and P4.

18. The composition of claim 16 , further comprising a compound of formula:

19. A composition comprising Fondaparinux sodium and a compound according to claim 1 .

20. A composition comprising Fondaparinux sodium and a compound selected from compounds of Formula I:

in which

(a) R 1 is levulinyl (Lev), R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me;

(b) R 1 is tetrahydropyran (THP), R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me;

(c) R 1 is tetrahydropyran (THP), R 2 is —O − or a salt thereof, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof;

(d) R 1 is tetrahydropyran (THP), R 2 is —OSO 3 − or a salt thereof, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof;

(e) R 1 is tetrahydropyran (THP), R 2 is —OSO 3 − or a salt thereof, R 3 is H, R 4 is NH 2 , R 5 is methyl, and R 6 and R 7 are —CO 2 − or a salt thereof;

(f) R 1 is tetrahydropyran (THP), R 2 is —OSO 3 Na, R 3 is H, R 4 is NHSO 3 Na, R 5 is methyl, and R 6 and R 7 are —CO 2 Na; or

(g) R 1 is H, R 2 is —OAcetyl or —OBenzoyl, R 3 is benzyl, R 4 is N 3 (azide), R 5 is methyl, R 6 is —CO 2 CH 2 C 6 H 5 and R 7 is —CO 2 Me;

and combinations thereof.

Assignments (8)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 16, 2020
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
To: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
Reel/Frame 054440/0877 →
SECURITY AGREEMENT (NOTES) Recorded Nov 6, 2020
From: AVANTOR FLUID HANDLING, LLC; AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 054343/0414 →
SECURITY AGREEMENT Recorded Nov 29, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 044528/0960 →
SECURITY AGREEMENT Recorded Nov 28, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 044811/0400 →
RELEASE (REEL 040913 / FRAME 0118) Recorded Nov 27, 2017
From: CITIBANK, N.A.
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 044511/0265 →
SECURITY AGREEMENT Recorded Dec 14, 2016
From: RELIABLE BIOPHARMACEUTICAL, LLC
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040913/0118 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: RELIABLE BIOPHARMACEUTICAL CORPORATION
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 040277/0548 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2016
From: RELIABLE BIOPHARMACEUTICAL CORPORATION
To: RELIABLE BIOPHARMACEUTICAL, LLC
Reel/Frame 040174/0564 →